Last 53.50 GBp
Change Today 0.00 / 0.00%
Volume 3.2K
REVO On Other Exchanges
As of 11:35 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

revolymer plc (REVO) Snapshot

53.50 GBp
Previous Close
53.50 GBp
Day High
53.50 GBp
Day Low
53.50 GBp
52 Week High
01/20/14 - 101.00 GBp
52 Week Low
04/19/13 - 47.50 GBp
Market Cap
Average Volume 10 Days
-0.10 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for REVOLYMER PLC (REVO)

Related News

No related news articles were found.

revolymer plc (REVO) Related Businessweek News

No Related Businessweek News Found

revolymer plc (REVO) Details

Revolymer plc designs, develops, and formulates polymers. The company’s products comprise chewing gum formulations, which are incorporated into the chewing gum; removable gums; and medicated gums, including caffeine and nicotine gums. It also focuses on the application of its polymer technologies in various applications consisting of confectionary and medicated gums; coatings and adhesives; household products; and personal care. It has operations in the United Kingdom, Ireland, Canada, Italy, and the United States. Revolymer plc is headquartered in Deeside, the United Kingdom.

36 Employees
Last Reported Date: 03/31/14

revolymer plc (REVO) Top Compensated Officers

Acting Chief Executive Officer, Chief Financi...
Total Annual Compensation: 196.0K GBP
Compensation as of Fiscal Year 2012.

revolymer plc (REVO) Key Developments

Revolymer plc Announces Consolidated Earnings Results for the Year Ended December 31, 2013

Revolymer plc announced consolidated earnings results for the year ended December 31, 2013. For the year, revenue was GBP 528,000 against GBP 176,000 a year ago. Group operating loss was GBP 5,477,000 against GBP 10,124,000 a year ago. Loss for the year before tax was GBP 5,284,000 against GBP 10,074,000 a year ago. Loss for the year was GBP 5,284,000 or 9.8 pence per basic and diluted share against GBP 10,074,000 or 25.2 pence per basic and diluted share a year ago. Net cash outflow from operating activities was GBP 4,311,000 against GBP 4,270,000 a year ago. Purchase of property, plant and equipment was GBP 183,000 against GBP 75,000 a year ago.

Revolymer plc Announces Executive Changes, Effective from January 31, 2014

Revolymer plc announced that its CEO, Dr. Roger Pettman, will leave the company with effect from January 31, 2014. Dr. Pettman has been CEO of the business since its inception in 2005. In the meantime, Revolymer CFO and Company Secretary Rob Cridland will become acting CEO, working closely with Dr. David Pears, Chief Technology Officer, and Dr. Jonathan Swanston, who heads the commercialization of the company's nicotine gum globally.

Revolymer plc Signs Supply and Distribution Agreement with Amma Polska

Revolymer plc announced that it has signed a supply and distribution agreement for its nicotine gum products with Amma Polska for Poland, Hungary and the Czech and Slovak Republics. Under the terms of the agreement, Amma is responsible for marketing, sales and distribution within these countries.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REVO:LN 53.50 GBp 0.00

REVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for REVO.
View Industry Companies

Industry Analysis


Industry Average

Valuation REVO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 55.7x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 55.8x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REVOLYMER PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at